NasdaqGS:OPKHealthcare
OPKO Health (OPK) Stock Could Be 58.8% Undervalued After OPK8801001 Preclinical Update
OPKO Health (OPK) stock is in focus after OPKO Biologics shared preclinical results for its acromegaly candidate OPK8801001, highlighting strong, dose-dependent IGF-1 suppression and higher growth hormone receptor antagonism compared with existing therapy.
See our latest analysis for OPKO Health.
Following the ENDO 2026 update on OPK8801001, OPKO Health’s 30-day share price return of 27.27% and 90-day gain of 17.65% suggest building momentum. However, the 5-year total shareholder return, down...